AIM: To analyze whether prompt and appropriate empirical antibiotic (AEA) use is associated with mortality in cirrhotic patients with bacteremia. METHODS: A total of 102 episodes of bacteremia in 72 patients with cirrhosis were analyzed. AEA was defined as a using or starting an antibiotic appropriate to the isolated pathogen at the time of bacteremia. The primary endpoint was 30-d mortality. RESULTS: The mortality rate at 30 d was 30.4% (31/102 episodes). Use of AEA was associated with better survival at 30 d (76.5% vs 46.9%, P = 0.05), and inappropriate empirical antibiotic (IEA) use was an independent factor associated with increased mortality (OR = 3.24; 95%CI: 1.50-7.00; P = 0.003, adjusted for age, sex, Child-Pugh Class, gastrointestinal bleeding, presence of septic shock). IEA use was more frequent when the isolated pathogen was a multiresistant pathogen, and when infection was healthcare-related or hospital-acquired. CONCLUSION: AEA use was associated with increased survival of cirrhotic patients who developed bacteremia. Strategies for AEA use, tailored according to the local epidemiological patterns, are needed to improve survival of cirrhotic patients with bacteremia.
AIM: To analyze whether prompt and appropriate empirical antibiotic (AEA) use is associated with mortality in cirrhotic patients with bacteremia. METHODS: A total of 102 episodes of bacteremia in 72 patients with cirrhosis were analyzed. AEA was defined as a using or starting an antibiotic appropriate to the isolated pathogen at the time of bacteremia. The primary endpoint was 30-d mortality. RESULTS: The mortality rate at 30 d was 30.4% (31/102 episodes). Use of AEA was associated with better survival at 30 d (76.5% vs 46.9%, P = 0.05), and inappropriate empirical antibiotic (IEA) use was an independent factor associated with increased mortality (OR = 3.24; 95%CI: 1.50-7.00; P = 0.003, adjusted for age, sex, Child-Pugh Class, gastrointestinal bleeding, presence of septic shock). IEA use was more frequent when the isolated pathogen was a multiresistant pathogen, and when infection was healthcare-related or hospital-acquired. CONCLUSION:AEA use was associated with increased survival of cirrhotic patients who developed bacteremia. Strategies for AEA use, tailored according to the local epidemiological patterns, are needed to improve survival of cirrhotic patients with bacteremia.
Authors: Javier Fernández; Juan Acevedo; Miriam Castro; Orlando Garcia; Carlos Rodríguez de Lope; Daria Roca; Marco Pavesi; Elsa Sola; Leticia Moreira; Anibal Silva; Tiago Seva-Pereira; Francesco Corradi; Jose Mensa; Pere Ginès; Vicente Arroyo Journal: Hepatology Date: 2012-04-04 Impact factor: 17.425
Authors: Ju Dong Yang; W Ray Kim; Ritika Coelho; Teresa A Mettler; Joanne T Benson; Schuyler O Sanderson; Terry M Therneau; Bohyun Kim; Lewis R Roberts Journal: Clin Gastroenterol Hepatol Date: 2010-09-08 Impact factor: 11.382
Authors: H J Park; Y-M Lee; K M Bang; S-Y Park; S M Moon; K-H Park; Y P Chong; S-H Kim; S-O Lee; S-H Choi; J-Y Jeong; J H Woo; Y S Kim Journal: Eur J Clin Microbiol Infect Dis Date: 2012-07-26 Impact factor: 3.267
Authors: Yaseen M Arabi; Saqib I Dara; Ziad Memish; Abdulmajeed Al Abdulkareem; Hani M Tamim; Nehad Al-Shirawi; Joseph E Parrillo; Peter Dodek; Stephen Lapinsky; Daniel Feinstein; Gordon Wood; Sandra Dial; Sergio Zanotti; Anand Kumar Journal: Hepatology Date: 2012-12 Impact factor: 17.425
Authors: Kim O Gradel; Ulrich S Jensen; Henrik C Schønheyder; Christian Østergaard; Jenny D Knudsen; Sonja Wehberg; Mette Søgaard Journal: BMC Infect Dis Date: 2017-02-06 Impact factor: 3.090